Correspondence 0001193125-23-234349 from Ambrx Biopharma, Inc. (CIK 0001990550)
Ambrx Biopharma, Inc. (CIK 0001990550)
Date: Sept. 13, 2023 · CIK: 0001990550 · Accession: 0001193125-23-234349
AI Filing Summary & Sentiment
File numbers found in text: 333-274230
Show Raw Text
CORRESP 1 filename1.htm CORRESP New Ambrx Biopharma Inc. 10975 North Torrey Pines Road La Jolla, CA 92037 September 13, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: New Ambrx Biopharma Inc. Registration Statement on Form S-4 File No. 333-274230 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, New Ambrx Biopharma Inc. (the “Company”) hereby requests acceleration of the effective date of the above referenced Registration Statement to 4:00 p.m., Eastern Time, on September 15, 2023, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Skadden, Arps, Slate, Meagher & Flom LLP, request by telephone that such Registration Statement be declared effective. Please contact Raymond Bogenrief, of Skadden, Arps, Slate, Meagher & Flom LLP, special counsel to the Company, at (312) 407-0550, as soon as the Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter. Sincerely, /s/ Daniel J. O’Connor Daniel J. O’Connor President and Chief Executive Officer